Cost-Utility Analysis of Natalizumab as First-Line Treatment of Highly-Active Relapsing-Remitting Multiple Sclerosis in the Brazilian Public Healthcare System.
Alves J, Machado M
Value Health. 2015 Nov; 18(7):A878. Epub 2015 Oct 20. PMID: 26534704.Abstract